The definitive diagnosis of BPDCN can be based on the immunohistochemical results, which are characterized by the expression of CD4, CD56, and the pDC-specific markers CD123, TCL-1, and BDCA-2/CD303 and lack of lymphoid and myeloid markers. Here, CD4 is linked to CD4+/CD56+ hematodermic neoplasm.